Addressing concerns about changing the route of antimicrobial administration from intravenous to oral in adult inpatients

Canadian Journal of Hospital Pharmacy

Volumn 68, Issue 4, 2015, Pages 318-326

  Béïque, Lizanne ^a   Zvonar, Rosemary ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antimicrobial stewardship programs; Antimicrobials; Intravenous therapy; IV to po transition; Oral therapy; Step down

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; CLINICAL PRACTICE; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEEDING APPARATUS; HOSPITAL PATIENT; HUMAN; PATIENT EDUCATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84959527505     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: 10.4212/cjhp.v68i4.1472     Document Type: Review

References (59)

1. Goff DA, Bauer KA, Reed EE, Stevenson KB, Taylor JJ, West JE. Is the "low-hanging fruit" worth picking for antimicrobial stewardship programs? Clin Infect Dis. 2012;55(4):587-92.
2. Lau BD, Pinto BL, Thiemann DR, Lehmann CU. Budget impact analysis of conversion from intravenous to oral medication when clinically eligible for oral intake. Clin Ther. 2011;33(11):1792-6.
3. Kuper K. Intravenous to oral therapy conversion. In: Murdaugh LB. Competence assessment tools for health-system pharmacies. 4th ed. Bethesda (MD): American Society of Health-System Pharmacists; 2008. p. 347-60.
4. Lelekis M, Gould IM. Sequential antibiotic therapy for cost containment in the hospital setting: why not? J Hosp Infect. 2001;48(4):249-57.
5. Burgess D. Antimicrobial regimen selection. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy a pathophysiological approach. 8th ed. Toronto (ON): The McGraw-Hills Companies; 2011. p. 1813-23.
6. Pillai S, Eliopoulos G, Moellering R. Principles of anti-infective therapy. In: Mandell G, Bennett J, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Philadelphia (PA): Churchill Livingston Elsevier; 2010. p. 267-78.
7. Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. Clin Ther. 2012;34(8):1667-73.
8. Sandberg T, Skoog G, Hermansson AB, Kahlmeter G, Kuylenstierna N, Lannergard A, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebocontrolled, non-inferiority trial. Lancet. 2012;380(9840):484-90.
9. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52.
10. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-S72.
11. Barlow GD, Nathwani D. Sequential antibiotic therapy. Curr Opin Infect Dis. 2000;13(6):599-607.
12. Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother. 2009;64(1):188-99.
13. Fraser Health Vascular Access Regional Shared Work Team; Hignell P. Peripheral intravenous initiation: self learning module. Version 5. Surrey (BC): Fraser Health; 2012 May [cited 2014 Aug. 13]. Available from: https://www.fraserhealth.ca/media/PeripheralIntravenousInitiation Module.pdf
14. Rojo D, Pinedo A, Clavijo E, Garcia-Rodriguez A, Garcia V. Analysis of risk factors associated with nosocomial bacteraemias. J Hosp Infect. 1999;42(2):135-41.
15. Safdar N, Maki DG. Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients. Chest. 2005;128(2):489-95.
16. Bamford KB, Desai M, Aruede MJ, Lawson W, Jacklin A, Franklin BD. Patients' views and experience of intravenous and oral antimicrobial therapy: room for change. Injury. 2011;42 Suppl 5:S24-S7.
17. Carratala J, Garcia-Vidal C, Ortega L, Fernandez-Sabe N, Clemente M, Albero G, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med. 2012;172(12):922-8.
18. Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs. 2008;68(17):2469-81.
19. Oosterheert JJ, Bonten MJM, Schneider MME, Buskens E, Lammers JW, Hustinx WMN, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006;333(7580):1193.
20. Desai M, Franklin BD, Holmes AH, Trust S, Richards M, Jacklin A, et al. A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay. BMC Infect Dis. 2006;6:94.
21. Fan J, de Lannoy IAM. Pharmacokinetics. Biochem Pharmacol. 2014;87(1):93-120.
22. ® [database on Internet]. Hudson (OH): Lexicomp Inc; © 1978-2014 [cited 2014 Aug. 14]. Available from: www.lexi.com/. Registration required to access content.
23. Voriconazole product monograph. Kirkland (QC): Pfizer Canada Inc; 2014 Oct. 30.
24. Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 2012;55(3):381-90.
25. Andes D, Lepak A. Editorial commentary: Antifungal therapeutic drug monitoring progress: getting it right the first time. Clin Infect Dis. 2012;55(3):391-3.
26. ® [database on Internet]. Bethesda (MD): American Society of Health-System Pharmacists, Inc: © 1959-2014 [cited 2014 Aug. 14]. Available from: www.ahfsdruginformation. com/. Registration required to access content.
27. Swartz MN. Clinical practice. Cellulitis. New Engl J Med. 2004;350(9):904-12.
28. Ankomah P, Levin BR. Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections. Proc Natl Acad Sci U S A. 2014;111(23):8331-8.
29. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2012;56(6):2795-805.
30. Azithromycin product monograph. Mississauga (ON): Actavis Pharma Company; 2014 Oct. 22.
31. Cefuroxime axetil product monograph. Mississauga (ON): GlaxoSmith Kline Inc; 2014 Jan 30.
32. Guidance for industry. Bioavailability and bioequivalence studies submitted in NDAs or INDs-general considerations. Draft guidance. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2014 [cited 2014 Feb. 3]. Available from: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf
33. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis. 2007;45 Suppl 95:S89-S95.
34. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy. 2002;22(10):1216-25.
35. Chin TW, Vandenbroucke A, Fong IW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother. 1995;39(1):28-33.
36. Shaffer JL, Kershaw A, Houston JB. Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease. Br J Clin Pharmacol. 1986;21(4):431-5.
37. Pelz RK, Lipsett PA, Swoboda SM, Merz W, Rinaldi MG, Hendrix CW. Enteral fluconazole is well absorbed in critically ill surgical patients. Surgery. 2002;131(5):534-40.
38. Posaconazole product monograph. Kirkland (QC): Merck Canada Inc; 2014 Oct. 20.
39. Vanstraelen K, Verhaegen J, Peetermans WE, Willems L, Spriet I. Stimulation of the i.v. to oral switch of bioavailable drugs by phone calls in a Belgian tertiary care hospital. Acta Clin Belg. 2013;68(3):179-82.
40. Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg. 1996;223(3):303-15.
41. Davey P, Nathwani D. Sequential antibiotic therapy: the right patient, the right time and the right outcome. J Infect. 1998;37 Suppl 1:37-44.
42. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-64.
43. Aboltins CA, Hutchinson AF, Sinnappu RN, Cresp D, Risteski C, Kathirgamanathan R, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. J Antimicrob Chemother. 2015;70(2):581-6.
44. Babouee FB, Elzi L, Kolbe M, Frei R, Weisser M, Scharen S, et al. Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis? BMC Infect Dis. 2014;14:226.
45. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54(3):393-407.
46. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):1-10.
47. Al-Omari A, Cameron DW, Lee C, Corrales-Medina VF. Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review. BMC Infect Dis. 2014;14:140.
48. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 1998;37(3):840-51.
49. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet. 1998;34(1):25-56.
50. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother. 1995;36(2):395-401.
51. Reintam A, Parm P, Redlich U, Tooding LM, Starkopf J, Kohler F, et al. Gastrointestinal failure in intensive care: a retrospective clinical study in three different intensive care units in Germany and Estonia. BMC Gastroenterol. 2006;6:19.
52. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24-34.
53. Laverdiere M, Bow EJ, Rotstein C, Autmizguine J, Broady R, Garber G, et al. Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol. 2014;25(6):327-43.
54. McIntyre CM, Monk HM. Medication absorption considerations in patients with postpyloric enteral feeding tubes. Am J Health Syst Pharm. 2014;71(7):549-56.
55. Beckwith MC, Feddema SS, Barton RG, Graves C. A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods. Hosp Pharm. 2004;39(3):225-37.
56. White R, Bardnam V. Handbook of drug administation via enteral feeding tubes. 2nd ed. London (UK): Pharmaceutical Press; 2011.
57. Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother. 1996;40(1):6-10.
58. Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65(24):2347-57.
59. Chui D, Cheng L, Tejani AM. Clinical equivalency of ciprofloxacin 750 mg enterally and 400 mg intravenously for patients receiving enteral feeding: systematic review. Can J Hosp Pharm. 2009;62(2):127-34.